Cargando…

Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States

Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. A better understanding of HCV disease progression and the associated cost can help the medical community manage HCV and develop treatment strategies in light of the emergence of se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Razavi, Homie, ElKhoury, Antoine C, Elbasha, Elamin, Estes, Chris, Pasini, Ken, Poynard, Thierry, Kumar, Ritesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Subscription Services, Inc., A Wiley Company 2013
Materias:	Viral Hepatitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763475/ https://www.ncbi.nlm.nih.gov/pubmed/23280550 http://dx.doi.org/10.1002/hep.26218

Ejemplares similares

HCV disease burden and population segments in Switzerland
por: Bihl, Florian, et al.
Publicado: (2021)

Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals?
por: Kondili, Loreta A., et al.
Publicado: (2018)

Peripheral neuropathy after viral eradication with direct‐acting antivirals in chronic HCV hepatitis: A prospective study
por: Zanone, Maria M., et al.
Publicado: (2021)

Histological changes in HCV antibody–positive, HCV RNA–negative subjects suggest persistent virus infection
por: Hoare, Matthew, et al.
Publicado: (2008)

Mucosal‐associated invariant T‐cell frequency and function in blood and liver of HCV mono‐ and HCV/HIV co‐infected patients with advanced fibrosis
por: Beudeker, Boris J. B., et al.
Publicado: (2017)

Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population
por: Schmidbauer, Caroline, et al.
Publicado: (2020)

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
por: Feld, Jordan J., et al.
Publicado: (2018)

Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C
por: Tsochatzis, Emmanuel A, et al.
Publicado: (2014)

Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens
por: Reddy, K. Rajender, et al.
Publicado: (2017)

SNP rs688 within the low‐density lipoprotein receptor (LDL‐R) gene associates with HCV susceptibility
por: Steba, Gaby S., et al.
Publicado: (2018)

Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials
por: Brown, Ashley, et al.
Publicado: (2019)

Feasibility and effectiveness of HCV viraemia testing at harm reduction sites in Georgia: A prospective three‐arm study
por: Shilton, Sonjelle, et al.
Publicado: (2022)

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies
por: Yao, Betty B., et al.
Publicado: (2020)

Predicting hepatitis B e Antigen seroconversion after pregnancy—The SydPregScore
por: Thilakanathan, Cynthuja, et al.
Publicado: (2022)

Hepatitis E virus and fulminant hepatitis–a virus or host-specific pathology?
por: Smith, Donald B, et al.
Publicado: (2015)

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients
por: Chayama, Kazuaki, et al.
Publicado: (2015)

Chronic Hepatitis E is associated with cholangitis
por: Beer, Andrea, et al.
Publicado: (2019)

Branched-chain amino acids reduce hepatic iron accumulation and oxidative stress in hepatitis C virus polyprotein-expressing mice
por: Korenaga, Masaaki, et al.
Publicado: (2015)

Over time evaluation of glycaemic control in direct‐acting antiviral‐treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis
por: Cacciola, Irene, et al.
Publicado: (2021)

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis
por: Kumada, Hiromitsu, et al.
Publicado: (2015)

Global Distribution and Prevalence of Hepatitis C Virus Genotypes
por: Messina, Jane P, et al.
Publicado: (2015)

Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan
por: Chen, Chi‐Yi, et al.
Publicado: (2021)

Spatial epidemiology of hepatitis C virus infection in Egypt: Analyses and implications
por: Cuadros, Diego F, et al.
Publicado: (2014)

Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt
por: Benova, Lenka, et al.
Publicado: (2015)

IFITM1 is a tight junction protein that inhibits hepatitis C virus entry,
por: Wilkins, Courtney, et al.
Publicado: (2013)

Paracrine Signals From Liver Sinusoidal Endothelium Regulate Hepatitis C Virus Replication
por: Rowe, Ian A, et al.
Publicado: (2014)

Type I interferon rapidly restricts infectious hepatitis C virus particle genesis
por: Meredith, Luke W, et al.
Publicado: (2014)

Chronic hepatitis C viral infection subverts vaccine‐induced T‐cell immunity in humans
por: Kelly, Christabel, et al.
Publicado: (2016)

microRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C
por: Van Keuren‐Jensen, Kendall R., et al.
Publicado: (2015)

Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa?
por: Desalegn, Hailemichael, et al.
Publicado: (2017)

Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles
por: Oliveira, Catarina, et al.
Publicado: (2017)

Treatment induced clearance of hepatitis E viruses by interferon‐lambda in liver‐humanized mice
por: Sari, Gulce, et al.
Publicado: (2021)

Estimating the Net Contribution of Interleukin-28B Variation to Spontaneous Hepatitis C Virus Clearance
por: di Iulio, Julia, et al.
Publicado: (2011)

DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection
por: Burza, Maria Antonella, et al.
Publicado: (2015)

The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment
por: Kandeel, Amr, et al.
Publicado: (2016)

Effect of Immune Pressure on Hepatitis C Virus Evolution: Insights From a Single-Source Outbreak
por: Merani, Shahzma, et al.
Publicado: (2011)

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus
por: van de Ven, Nikolien, et al.
Publicado: (2015)

Activated Macrophages Promote Hepatitis C Virus Entry in a Tumor Necrosis Factor-Dependent Manner
por: Fletcher, Nicola F, et al.
Publicado: (2014)

Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection
por: Lattimore, Sam, et al.
Publicado: (2014)

Expression of scavenger receptor‐AI promotes alternative activation of murine macrophages to limit hepatic inflammation and fibrosis
por: Labonte, Adam C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k012sdrc9h0u2i0hi2m1l2tu67